Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the …
BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common subtype of
Non-Hodgkins lymphomas (NHL). The outcome of these patients shows a wide variation …
Non-Hodgkins lymphomas (NHL). The outcome of these patients shows a wide variation …
Peptide antibodies in clinical laboratory diagnostics
NH Trier, G Houen - Advances in clinical chemistry, 2017 - Elsevier
Peptide antibodies, with their high specificities and affinities, are invaluable reagents for
peptide and protein recognition in biological specimens. Depending on the application and …
peptide and protein recognition in biological specimens. Depending on the application and …
[HTML][HTML] Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
Z Liu, ZY Xu-Monette, X Cao, GC Manyam, X Wang… - Modern Pathology, 2015 - Elsevier
Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety
of human neoplasms. The prognostic significance of survivin expression in diffuse large B …
of human neoplasms. The prognostic significance of survivin expression in diffuse large B …
Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B‐cell lymphoma (DLBCL)
O Markovic, D Marisavljevic… - European journal of …, 2011 - Wiley Online Library
Background: Apoptosis‐related proteins might play an important role in the pathogenesis of
lymphoma and sensibility to chemotherapy (CH) in patients with non‐Hodgkin's lymphoma …
lymphoma and sensibility to chemotherapy (CH) in patients with non‐Hodgkin's lymphoma …
Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics
JJ Anderson, S Fordham… - International …, 2009 - spandidos-publications.com
Diffuse large B-cell lymphoma (DLBCL) forms a heterogeneous collection of aggressive non-
Hodgkin's Lymphoma in which three principle classes of neoplasia have been defined …
Hodgkin's Lymphoma in which three principle classes of neoplasia have been defined …
Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP
Survivin is an inhibitor of apoptosis whose expression may be associated with inferior
outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab …
outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab …
Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma
AML Bedewy, MMA Elgammal, MML Bedewy… - Annals of …, 2013 - Springer
The soluble decoy receptor 3 (DcR3) is a member of the tumor necrosis factor receptor
superfamily whose overexpression has been observed in several human malignancies …
superfamily whose overexpression has been observed in several human malignancies …
Survivin expression in patients with newly diagnosed nodal diffuse large B cell lymphoma (DLBCL)
O Markovic, D Marisavljevic, V Cemerikic-Martinovic… - Medical Oncology, 2012 - Springer
Survivin is one of the inhibitors of apoptosis proteins (IAP) that might play an important role
in the pathogenesis of diffuse large B cell lymphoma (DLBCL). The present study was …
in the pathogenesis of diffuse large B cell lymphoma (DLBCL). The present study was …
INCENP (inner centromere protein) is overexpressed in high grade non-Hodgkin B-cell lymphomas
S Barbanis, M Ioannou, E Kouvaras… - Pathology & Oncology …, 2009 - Springer
Inner centromere protein (INCENP) is a member of the Chromosomal Passenger Complex
(CPC), which is a four member protein complex essential for proper completion of mitosis …
(CPC), which is a four member protein complex essential for proper completion of mitosis …
[HTML][HTML] Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab
NM Guevara Arismendy, PE Jaramillo Arbeláez… - Iatreia, 2013 - scielo.org.co
Introducción: la inclusión del rituximab para el tratamiento del linfoma B difuso de células
grandes generó la necesidad de reevaluar los factores pronósticos que se empleaban …
grandes generó la necesidad de reevaluar los factores pronósticos que se empleaban …